Search Follow us

Threshold Pharmaceuticals (THLD)

Business description

Threshold is focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Ph III for STS and pancreatic cancer and earlier trials in other cancers. It is partnered with Merck KGaA.

Tarloxotinib advances into two Phase II trials

Update | Pharmaceutical & healthcare | 15/09/2015

Tarloxitinib (TH-4000), Threshold’s earlier-stage hypoxia asset, has now started two Phase II studies, as planned. With active development now ongoing we include an indicative valuation for this asset in our rNPV, which has increased to $1,023m ($14.3/share). Tarloxotinib broadens and diversifies Threshold’s pipeline beyond evofosfamide, where we continue to expect the number of events needed for analysis of the Phase III STS and pancreatic trials should be reached in H215, with data shortly after.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.US$35.6m
Last closeUS$0.498
High / Low (52 weeks)US$1.3 / US$0.4
Stock market listingUS
Forecast net cash (US$m)31
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual26.6(1.2)(2.6)
Relative *24.2(4.6)(14.3)

* % Relative to local index

Company news